Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) believes it has taken full advantage of its recent prior discovery in developing small molecule drugs that activate NR2F6. The Company recently reported that it identified key structural elements in small molecules that make them active and specific towards the NR2F6 target. Now, further chemical testing has revealed dozens of compounds which activate NR2F6 which contain the key motif discovered.